Skip to main content

Table 1 Demographics and other baseline characteristics

From: Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

  Statistic Placebo
(N = 60)
PQ912
(N = 60)
Age (years) Mean (SD) 72 (7) 70.8 (8)
Sex
 Female n (%) 28 (47) 36 (60)
 Male n (%) 32 (53) 24 (40)
MMSE Mean (SD) 24.8 (3) 25.2 (3)
APoE
 E4 n (%) 43 (72) 38 (63)
  1. APoE apolipoprotein E, MMSE Mini Mental State Examination, N number of subjects in population, n number of subjects, SD standard deviation
\